New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
Presented by Edward Li, PharmD, MPH, BCOP
University of New England College of Pharmacy, Portland, Maine
Presenter’s disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2018;9(3):276–281 |
© 2018 Harborside™
Therapies approved for solid tumors by the FDA from 2016 to 2017 have transformed the way clinicians practice medicine. Dr. Li from the University of New England College of Pharmacy provides the latest clinical trial data and insights on the emergence of new drug classes such as PARP inhibitors and PD-1/PD-L1 inhibitors.
For access to the full length article, please sign in